American Journal of Psychiatry· 2026Q1· Review
Artificial Intelligence as the Computational Framework for Adaptive Closed-Loop Neuromodulation in Psychiatry
- 1citations
- Q1SCImago
- 2026year
Short summary
Artificial intelligence (AI) can integrate multimodal sensing, infer patient state, predict treatment response, and guide therapeutic adaptation for personalized neuromodulation in psychiatry, overcoming challenges of heterogeneous and indirectly measured symptoms.
AI-generated from the title and abstract; the full text is not read.
Key points
- AI can enable adaptive neuromodulation by linking multimodal sensing, patient state inference, and treatment response prediction.
- Psychiatric disorders present challenges due to symptom heterogeneity and indirect, incomplete measurements.
- Interpretability and clinician/patient oversight are crucial for trust and safety in AI-driven neuromodulation.
- Clinical evidence is currently limited to small proof-of-concept studies, requiring further validation.
AI-generated from the title and abstract; the full text is not read.
Abstract
Adaptive neuromodulation offers a path toward personalized neuropsychiatric treatment by allowing therapy to respond to clinically meaningful neurophysiological and behavioral changes. Its clearest clinical precedents are responsive neurostimulation for epilepsy and adaptive deep brain stimulation for movement disorders. Both rely on signals that can be measured reliably and linked directly to stimulation. Psychiatric disorders pose a different problem: symptoms are heterogeneous, evolve over multiple timescales, and are observed only indirectly through noisy and incomplete measurements. Artificial intelligence can provide data-driven components of an adaptive neuromodulation system, connecting multimodal sensing, inference of patient state, prediction of treatment response, and constrained therapeutic adaptation. Interpretability is required throughout to support clinician and patient trust. Clinical evidence, however, remains limited to small proof-of-concept studies. Translation to practice will require replicated biomarkers and prospective multisite validation. It will also require explicit management of uncertainty and system designs that match adaptation to symptom and treatment timescales. Clinician and patient oversight must be preserved throughout, alongside safety constraints and governance across the treatment life cycle. This review presents a system-design view of how these components combine into a single adaptive architecture for psychiatric neuromodulation.
The authors' abstract, as published at the source. American Journal of Psychiatry, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Neurology (Medicine)
NeurologyMedicine